Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1358894 in borderline personality disorder (phase II, randomized, double-blind, placebo-controlled)
2020-000078-12Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bi 1358894 in borderline personality disorder (BPD) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in ZAN-BPD total score. Started Jun 2020; status: completed.
02
Drugs
bi 1358894
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on 2020-000078-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000078-12.